Checkpoint Agrees To Sun Pharma Buyout

Fierce Pharma Asia—Takeda's oncology focus; Sun's Checkpoint buy; Ono-Ionis antisense deal
Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an FDA-approved PD-L1 inhibitor. | Takeda is sharpening its oncology focus amid an R&D revamp.
Checkpoint Agrees To Sun Pharma Buyout: This Deal Suits Both Parties
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn an additional $0.7 with the CVR.
India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million
India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics, a U.S.-based immunotherapy and targeted oncology company, for $355 million. The deal is in line with Sun Pharma's active push in recent years to expand its oncology and immunotherapy portfolio through several acquisitions and collaborations.
Sun Pharma to acquire Checkpoint Therapeutics Inc for up to $355 million
Mumbai-based Sun Pharmaceutical Industries has entered into an agreement with Checkpoint Therapeutics Inc, to acquire the immunotherapy and targeted-oncology company for a consideration of up to $355 million ( ₹3,
Checkpoint Therapeutics jumps after deal to be acquired by Sun Pharma
Shares of Checkpoint Therapeutics (CKPT) have jumped $1.59, or 64%, to $4.06 in Monday morning trading after the company and Sun Pharmaceutical
Sun Pharma to acquire US oncology compony for over Rs 3,000 crore
Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhance Sun Pharma's specialty portfolio, including UNLOXCYT,
Sun Pharma is betting big on speciality. Will it pay off?
Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for ...
Indian Billionaire Dilip Shanghvi’s Sun Pharma To Buy U.S. Cancer Drug Maker For $355 Million
Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...
NJBIZ23h
Sun Pharma expanding Princeton HQ with $5.2M in tax credits
The New Jersey Economic Development Authority board March 12 approved $5.24 million in tax credits under the Emerge Program ...
Sun Pharmaceutical Industries climbs Wednesday, outperforms competitors
Sun Pharmaceutical Industries Ltd. closed 14.48% below its 52-week high of 1,960.20 rupees, which the company reached on ...
New Jersey Business Magazine2h
Emerge Program Secures Sun Pharma’s Presence in NJ
The NJEDA Board approved tax credits under the Emerge Program to support Sun Pharmaceutical Industries Inc.’s plan to open a new ...
Fierce Pharma4d
On the heels of FDA nod for cancer drug, Sun Pharma buys Checkpoint Therapeutics for up to $416M
Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...
Indian pharma ramps up US acquisitions amid regulatory and market shifts
Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...
Sun Pharmaceutical Industries climbs Thursday, outperforms competitors
Sun Pharmaceutical Industries Ltd. closed 14.10% below its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.
Sun Pharma Share Price Live Updates: Sun Pharma's Volume Comparison
Stay up-to-date with the Sun Pharma Stock Liveblog, your trusted source for real-time updates and thorough analysis of a ...